Clinical Cancer Research Prevention Award Frontiers in Basic Cancer Research
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shirakawa, T.
Right arrow Articles by Gotoh, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shirakawa, T.
Right arrow Articles by Gotoh, A.
Clinical Cancer Research Vol. 10, 4342-4348, July 1, 2004
© 2004 American Association for Cancer Research


Experimental Therapeutics, Preclinical Pharmacology

A Cox-2 Promoter-Based Replication-Selective Adenoviral Vector to Target the Cox-2-Expressing Human Bladder Cancer Cells

Toshiro Shirakawa1,–3, Katsuyuki Hamada4, Zhujun Zhang2, Hiroshi Okada5, Masatoshi Tagawa6, Sadao Kamidono1, Masato Kawabata2 and Akinobu Gotoh1,–3

1 Division of Urology, Department of Organs Therapeutics, Faculty of Medicine, Kobe University Graduate School of Medicine, Kobe; 2 International Center for Medical Research, and 3 Department of Clinical Genetics, Kobe University School of Medicine, Kobe; 4 Department of Gynecology, Ehime University School of Medicine, Tokyo, Japan; 5 Department of Urology, Teikyo University School of Medicine, Matsuyama, Japan; and 6 Division of Pathology, Chiba Cancer Center Research Institute, Chiba, Japan

ABSTRACT

Purpose: Cyclooxygenase-2 (Cox-2), an enzyme that catalyzes the synthesis of prostaglandins, is overexpressed in a variety of premalignant and malignant conditions, including urinary bladder cancer. In the present study, we examined the feasibility of using Cox-2 promoter-based replication-selective adenovirus for targeting bladder cancer cells that express Cox-2 transcriptional activity.

Experimental Design: A series of human cancer cell lines, including three bladder cancer cell lines (KK47, T24, and 5637), were evaluated for their Cox-2 and CAR (the Coxsackievirus and adenovirus receptor) mRNA expression levels by quantitative real-time PCR. AdE3-cox2–327, a replication-selective adenovirus in which the expression of E1a is controlled by the Cox-2 promoter, was generated, and its tissue-specific activity was tested in vitro and in vivo.

Results: Three bladder cancer cell lines express higher levels of Cox-2 mRNA than does the human prostate cancer cell line PC3, the primary cultured human benign prostatic fibroblast, PF cells, and the human colon cancer cell line Colo320. Relatively higher expression of CAR mRNA was detected in the KK47, 5637, respectively, and Colo320 than in the T24, PC-3, and PF cells. In vitro assays revealed significant growth suppression of both Cox-2- and CAR-expressing bladder cancer cells KK47 and 5637 in comparison with the other cells that lack Cox-2 expression and/or CAR expression.

Conclusions: The present study demonstrated both specificity and efficacy of AdE3-cox2–327, a selectively replicated adenovirus, toward the Cox-2-expressing bladder cancer cells in vitro and in vivo. We also found that CAR expression in the target cancer cells is an important factor for the efficacy of selectively replicated adenovirus-based gene therapy.




This article has been cited by other articles:


Home page
Clin. Cancer Res.Home page
E. G. Cafferata, D. R. Maccio, M. V. Lopez, D. L. Viale, C. Carbone, G. Mazzolini, and O. L. Podhajcer
A Novel A33 Promoter-Based Conditionally Replicative Adenovirus Suppresses Tumor Growth and Eradicates Hepatic Metastases in Human Colon Cancer Models
Clin. Cancer Res., May 1, 2009; 15(9): 3037 - 3049.
[Abstract] [Full Text] [PDF]


Home page
Arch Otolaryngol Head Neck SurgHome page
T. Nakagawa, H. Tanaka, T. Shirakawa, A. Gotoh, Y. Hayashi, K. Hamada, M. Tsukuda, and K.-i. Nibu
Cyclooxygenase 2 Promoter-Based Replication-Selective Adenoviral Vector for Hypopharyngeal Cancer
Arch Otolaryngol Head Neck Surg, March 1, 2009; 135(3): 282 - 286.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
J. Leja, H. Dzojic, E. Gustafson, K. Oberg, V. Giandomenico, and M. Essand
A Novel Chromogranin-A Promoter-Driven Oncolytic Adenovirus for Midgut Carcinoid Therapy
Clin. Cancer Res., April 15, 2007; 13(8): 2455 - 2462.
[Abstract] [Full Text] [PDF]


Home page
Arch Otolaryngol Head Neck SurgHome page
H. Tanaka, T. Shirakawa, Z. Zhang, K. Hamada, A. Gotoh, and K.-i. Nibu
A Replication-Selective Adenoviral Vector for Head and Neck Cancers
Arch Otolaryngol Head Neck Surg, July 1, 2005; 131(7): 630 - 634.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
Z.-Z. Su, D. Sarkar, L. Emdad, G. J. Duigou, C. S. H. Young, J. Ware, A. Randolph, K. Valerie, and P. B. Fisher
Targeting gene expression selectively in cancer cells by using the progression-elevated gene-3 promoter
PNAS, January 25, 2005; 102(4): 1059 - 1064.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2004 by the American Association for Cancer Research.